Accelerating Anticancer Agent Development and Validation Workshop (AAADV)

Goals and Objectives:

  1. To expedite the development and validation processes for new anticancer and cancer prevention agents.
  2. To educate investigators, so new agents may be made available to patients at a more efficient rate more rapidly in the future.
  3. To improve understanding of cancer drug development strategies to lead to a series of pivotal clinical trials demonstrating efficacy and patient benefit.

Who Should Attend:

  • Industry: Registrants should be involved in drug development.
  • Government: Registrants should be employed by an U.S. government agency and be involved in oncology drug discovery or development.
  • Academic: Registrants should be employed by a recognized academic institution and be involved or have an interest in oncology drug discovery and/or development. Previous or current experience in the conduct of clinical trials is helpful, but not required.
  • Advocates: Consumer and/or patient advocates should be sponsored by a nationally recognized advocacy organization or foundation. Advocates should have a background in clinical trial design and the role of the advocate in the development process.


ww.acceleratingworkshop.orgdisclaimer icon


If to Duke:

If to FDA:

  • Jura Viesulas, MS, EdD
    Office of Hematology and Oncology Products
    Bldg. 22 Room 2200
    10903 New Hampshire Avenue
    Food and Drug Administration
    Silver Spring, MD 20993


Page Last Updated: 02/05/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English